Skip to content
Medical Health Aged Care, Mental Health

Review highlights significant gaps in suicide prevention technology

Charles Darwin University 2 mins read

Researchers have found users need to be included more in the development of suicide prevention technology, following a review with Charles Darwin University (CDU).

Codesign of Digital Health Tools for Suicide Prevention: A Scoping Review by CDU and the University of Bradford in the United Kingdom examined the extent codesign and experts-by-experience were used in the development of suicide prevention technology.

Codesign is defined as a collaboration between researchers and end users from the beginning of development. Experts-by-experience is defined as people who have recent personal experience of using and caring for someone who uses health, mental health and/or social care services.

The review examined 61 articles and records on suicide prevention technology, published between November 2022 and March 2023.

Lead author and CDU Associate Professor of Social Work Dianne Wepa said the review found a disconnect between developers, researchers, and experts-by-experience.

The findings also revealed codesign was not included as a methodology in the development of suicide prevention technology.

“Given the exponential rise of digital solutions for suicide prevention, there appears however to be a disconnect between bringing the technology to market and involving experts-by-experience or service users as codesigners,” Associate Professor Wepa said.

With a rapidly evolving technological environment, understanding the place and space of experts-by-experience in suicide prevention requires urgent attention.

“Authentic involvement requires experts-by-experience as co-authors and end-to-end partners from design, implementation and evaluation of digital health tools for suicide prevention.”

The review also found the digital divide - the unequal access to technology - could worsen in the future and hinder access to suicide prevention technology.

“The digital divide is noteworthy as a future concern as countries such as the United Kingdom are phasing out 2G and 3G networks in 2023 to make room for faster 5G networks,” Associate Professor Wepa said.

“The implications for those on low incomes and experiencing mental distress may not be visible to the public as access to digital platforms in the future will require uninterrupted connectivity through smartphones and internet access.”

The review is part of a three-phase study into codesign of digital health tools. Associate Professor Wepa said results from the scoping review would inform phase three of the study, a funding application to codesign a proof-of-concept digital health tool for suicide prevention.

Codesign of Digital Health Tools for Suicide Prevention: A Scoping Review was published in the British Journal of Healthcare and Medical Research on World Suicide Prevention Day.


Contact details:

Raphaella Saroukos she/her
Communications Officer
Marketing, Media & Communications
Larrakia Country
T: +61 8 8946 6721
E: [email protected]
W: cdu.edu.au

Media

More from this category

  • Medical Health Aged Care
  • 10/03/2026
  • 20:11
Ferring Pharmaceuticals

For the First Time, Ferring Reports Revenue of Over €2.5 Billion in 2025

Ferring’s total revenues for 2025 exceeded €2.5 billion, an increase of 10% from 2024, mainly driven by our flagship product Menopur® Continued ramp-up in…

  • Contains:
  • Legal, Medical Health Aged Care
  • 10/03/2026
  • 17:30
Maddens Lawyers

Thousands register to participate in the Dr Lanzer Class Action

Patients who underwent cosmetic surgery at the Lanzer Clinics have until 4.00pm Friday 10 April to register or opt out of a class action set for trial in the Supreme Court of Victoria in September. The class action alleges that Dr Daniel Lanzer and his colleagues Dr Daniel Aronov, Dr Ryan Wells, Dr Alieza Fallahi, Dr George Wong, and Dr Daniel Darbyshire engaged in misleading and negligent practices while performing cosmetic surgeries, with many former patients left with injuries and ongoing pain. Psychologist Candice Wainstein, who is the wife of Dr Aronov, is also a defendant. Maddens Lawyers principal Kathryn…

  • Contains:
  • Medical Health Aged Care
  • 10/03/2026
  • 16:28
Phebra

Phebra launches Rapiblyk® in Australian healthcare settings

Australian Pharmaceutical company Phebra (‘Company’) has announced the launch of Rapiblyk® (landiolol hydrochloride), an ultra‑short‑acting, cardio-selective receptor antagonist, indicated for rapid control of ventricular rate in patients with severe, acute cardiac arrhythmias (irregular rapid heart rate) in critical care settings. Clinical studies have demonstrated that Rapiblyk® enables safe, effective heart rate control with limited impact on blood pressure and inotropy (heart contractility). Rapiblyk® has a very short half life delivering a fast onset and offset of action. This provides clinicians with a higher level of precision in life-threatening situations. Phebra CEO Andre Vlok highlighted how Rapiblyk® strengthens the company's critical…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.